Merck bets $334m on Korea as Asia-Pacific biopharma hub

What happened: Merck opened a $334 million bioprocessing plant in Daejeon, South Korea, its largest life science investment in Asia-Pacific, to bring production closer to regional drugmakers. Key numbers: $334 million investment; 44,500-square-meter facility in Dungok, Daejeon. Why it matters: The plant is part of Merck's "in-region-for-region" strategy to shorten supply chains and give Asia-Pacific biopharma manufacturers greater supply confidence as they scale from development to commercial production.

Merck opened a $334 million bioprocessing plant in Daejeon, South Korea, its largest life science investment in Asia-Pacific, to bring production closer to regional drugmakers.

The plant is part of Merck's "in-region-for-region" strategy to shorten supply chains and give Asia-Pacific biopharma manufacturers greater supply confidence as they scale from development to commercial production.